Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis

• Published in: Annals of oncology Vol. 22; no. 9; pp. 2152 - 2154
• Main Authors: Thiery-Vuillemin, A., Montange, D., Kalbacher, E., Maurina, T., Nguyen, T., Royer, B., Bouchet, S., Bazan, F., Curtit, E., Pivot, X.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.09.2011; Oxford University Press
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Biological and medical sciences; Carcinoma, Renal Cell - metabolism; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Carcinoma, Renal Cell - therapy; Drug Monitoring; Emergency and intensive care: renal failure. Dialysis management; Humans; Indoles - administration & dosage; Indoles - pharmacokinetics; Intensive care medicine; Kidney Neoplasms - metabolism; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Kidney Neoplasms - therapy; Kidneys; Male; Mediastinal Neoplasms - drug therapy; Mediastinal Neoplasms - metabolism; Mediastinal Neoplasms - secondary; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - secondary; Pharmacology. Drug treatments; Pyrroles - administration & dosage; Pyrroles - pharmacokinetics; Renal Dialysis; Sunitinib; Tumors of the urinary system; Antineoplastic agent; Carcinoma; Hemodialysis; Metastasis; Extrarenal dialysis; Sunitinib; Grawitz tumor; Advanced stage; Antiangiogenic agent; Protein-tyrosine kinase; Monitoring; Kidney disease; Human; Urinary system disease; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Patient; Malignant tumor; Surveillance; Kidney cancer; Multikinase inhibitor; Pharmacokinetics; Cancer
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdr343